Author:
Meng Sibo,Xia Yuan,Li Mingying,Wu Yuyan,Wang Dongmei,Zhou Ying,Ma Daoxin,Ye Jingjing,Sun Tao,Ji Chunyan
Abstract
AbstractDiffuse large B-cell lymphoma (DLBCL) is malignant hyperplasia of B lymphocytes and standard care cannot satisfactorily meet clinical needs. Potential diagnostic and prognostic DLBCL biomarkers are needed. NCBP1 could bind to the 5ʹ-end cap of pre-mRNAs to participate in RNA processing, transcript nuclear export and translation. Aberrant NCBP1 expression is involved in the pathogenesis of cancers, but little is known about NCBP1 in DLBCL. We proved that NCBP1 is significantly elevated in DLBCL patients and is associated with their poor prognosis. Then, we found that NCBP1 is important for the proliferation of DLBCL cells. Moreover, we verified that NCBP1 enhances the proliferation of DLBCL cells in a METTL3-dependent manner and found that NCBP1 enhances the m6A catalytic function of METTL3 by maintaining METTL3 mRNA stabilization. Mechanistically, the expression of c-MYC is regulated by NCBP1-enhanced METTL3, and the NCBP1/METTL3/m6A/c-MYC axis is important for DLBCL progression. We identified a new pathway for DLBCL progression and suggest innovative ideas for molecular targeted therapy of DLBCL.
Funder
National Natural Science Foundation of China
Young Taishan Scholars
Multidisciplinary Research and Innovation Team of Young Scholars of Shandong University
Distinguished Taishan Scholars in Climbing Plan
Major Research Plan of the National Natural Science Foundation of China
Key Program of Natural Science Foundation of Shandong Province
Fundamental Research Funds for Central Universities of the Central South University
Independently Cultivate Innovative Teams of Jinan, Shandong Province
Clinical Practical New Technology and Development Fund of Qilu Hospital, Shandong University
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献